Future Tumor Profiling Applications
The HTG EdgeSeq miRNA Whole Transcriptome Assay (v20) and HTG EdgeSeq Biomarker Oncology Panel provide comprehensive approaches to understand the miRNA and mRNAs which are playing a role in tumor biology. Other aspects of the tumor’s biology, including gene fusion / rearrangement status, protein expression profile, and DNA mutational status have been shown to be relevant to the behavior of the tumor.
HTG continues to innovate its core technology with these high value applications in mind. We have completed feasibility and are in development of protocols for measuring gene fusion panels. We have application protocols in research which may add DNA mutation detection capability to the HTG EdgeSeq system. We expect the HTG EdgeSeq system to be able to automate all of these applications with software upgrades that can be deployed on site with customers.
We believe there is a significant demand for improvement of lung cancer tumor profiling through minimization of tissue requirements, platform consolidation, and optimization of testing efficiency. We plan to develop and launch, as Research Use Only (RUO) or In Vitro Diagnostics (IVD) kits, the following individual tumor profiling products as part of our Total Lung Solution:
- Lung cancer fusions and rearrangements (including ALK, ROS1, and RET)
- Lung cancer hotspot mutations (including EGFR and KRAS)
- Lung cancer histology classifier
Our broader strategy for tumor profiling includes similar, focused portfolios of products by tumor type for breast, lung, prostate, colon and thyroid cancers.
For Research Use Only. Not for use in diagnostic procedures.